Form 4: Quince Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
Brendan Hannah, Chief Business Officer and COO of Quince Therapeutics, exercised stock options and disposed of shares on June 4, 2024.
Summary
- On June 4, 2024, Brendan Hannah, the Chief Business Officer and COO of Quince Therapeutics, exercised employee stock options to acquire 56,061 shares of common stock at a price of $0.55 per share.
- Following the transaction, Hannah directly owns 257,616 shares of Quince Therapeutics common stock.
- The exercised options were part of an employee stock option plan, vesting over a four-year period.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 06/04/2024 | Date of transaction: Brendan Hannah exercised stock options and disposed of shares. |
| 06/05/2024 | Date of signature on the Form 4 filing. |
| 03/27/2032 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.